Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Nathan

Showing results (31-40 of 297) with videos related to

Pageof 30
Sort By:
Current Opinion in Pulmonary Medicine|August 4, 2017
Pitfalls in developing new compounds for idiopathic pulmonary fibrosisSteven D Nathan, Fernando J Martinez
Annals of the American Thoracic Society|September 22, 2017
The Value and Application of the 6-Minute-Walk Test in Idiopathic Pulmonary FibrosisA Whitney Brown, Steven D Nathan
Chest|June 14, 2016
POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? YesChristopher S King, Steven D Nathan
Chest|August 5, 2015
Organ Donors: Making the Most of What Is OfferedSteven D Nathan, Christopher S King
The Lancet. Respiratory Medicine|September 8, 2016
Idiopathic pulmonary fibrosis: effects and optimal management of comorbiditiesChristopher S King, Steven D Nathan
The European Respiratory Journal|June 2, 2016
Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic sciencePaul M Hassoun, Steven D Nathan
Chest|July 9, 2023
ResponseSteven D Nathan, Aaron B Waxman
The Lancet. Respiratory Medicine|September 30, 2022
Phenotypes of idiopathic pulmonary arterial hypertensionKarim El-Kersh, Steven D Nathan
Expert Review of Respiratory Medicine|April 23, 2011
Pulmonary hypertension secondary to interstitial lung diseaseOksana A Shlobin, Steven D Nathan
Drug Design, Development and Therapy|July 26, 2014
Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?Steven D Nathan, Christopher S King
Pageof 30

Showing results (31-40 of 297) with videos related to

Sort By:
Pageof 30
Current Opinion in Pulmonary Medicine|August 4, 2017
Pitfalls in developing new compounds for idiopathic pulmonary fibrosisSteven D Nathan, Fernando J Martinez
Annals of the American Thoracic Society|September 22, 2017
The Value and Application of the 6-Minute-Walk Test in Idiopathic Pulmonary FibrosisA Whitney Brown, Steven D Nathan
Chest|June 14, 2016
POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? YesChristopher S King, Steven D Nathan
Chest|August 5, 2015
Organ Donors: Making the Most of What Is OfferedSteven D Nathan, Christopher S King
The Lancet. Respiratory Medicine|September 8, 2016
Idiopathic pulmonary fibrosis: effects and optimal management of comorbiditiesChristopher S King, Steven D Nathan
The European Respiratory Journal|June 2, 2016
Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic sciencePaul M Hassoun, Steven D Nathan
Chest|July 9, 2023
ResponseSteven D Nathan, Aaron B Waxman
The Lancet. Respiratory Medicine|September 30, 2022
Phenotypes of idiopathic pulmonary arterial hypertensionKarim El-Kersh, Steven D Nathan
Expert Review of Respiratory Medicine|April 23, 2011
Pulmonary hypertension secondary to interstitial lung diseaseOksana A Shlobin, Steven D Nathan
Drug Design, Development and Therapy|July 26, 2014
Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?Steven D Nathan, Christopher S King
Pageof 30